[{"id":"2c7078b6-9b43-4e89-b4ca-220ebb7b3987","acronym":"","url":"https://clinicaltrials.gov/study/NCT03734913","created_at":"2021-01-18T18:17:40.491Z","updated_at":"2024-07-02T16:36:42.875Z","phase":"Phase 1","brief_title":"A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT03734913","lead_sponsor":"Guangdong Zhongsheng Pharmaceutical Co., Ltd.","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 overexpression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZSP1602"],"overall_status":"Unknown status","enrollment":" Enrollment 65","initiation":"Initiation: 01/25/2019","start_date":" 01/25/2019","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 07/31/2021","study_completion_date":" 07/31/2021","last_update_posted":"2020-07-22"}]